biostudies-literatureUnknown12(3)Franchini MIn Winter 2020, Italy, and in particular the Lombardy region, was the first country in the Western hemisphere to be hit by the COVID-19 pandemic. Plasma from individuals recovered from COVID-19 (COVID-19 convalescent plasma, CCP) was the first therapeutic tool adopted to counteract the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In this retrospective cohort study, we report the experience of the city hospital of Mantua, Lombardy region, on the compassionate use of CCP in patients hospitalized for severe COVID-19. Between April 2020 and April 2021, 405 consecutive COVID-19 patients received 657 CCP units with a median anti-SARS-CoV-2 neutralizing antibody (nAb) titer of 160 (interquartile range (IQR), 80−320). Their median age was 68 years (IQR, 56−78 years), and 62% were Life (Basel, Switzerland)420https://www.ebi.ac.uk/biostudies/studies/S-EPMC8950373biostudies-literatureConvalescent Plasma for Hospitalized COVID-19 Patients: A Single-Center Experience.PMC8950373Garuti MPecoriello ABellocchio ECasari SFrigato MInglese FPuma GLucchini GTiecco GBianciardi LCastelli GPCervi GBellometti SAMontalto CCandini MVerzola ADonno GSpreafico FReggiani AStradoni RCodeluppi VGalavotti VBenazzi DMule ABertoletti RGreco GVesentini SAmbrosi GBeccaria MOn Behalf Of Convalescent Plasma Study GroupGlingani CZani MCostantino MTCrosato VGhirardini MBerselli ASantini TCarandina FPapalia DAScarduelli CFranchini MPagani MPresciuttini BPajola FCapuzzo EGrisolia GAmato MfalseConvalescent Plasma for Hospitalized COVID-19 Patients: A Single-Center Experience.In Winter 2020, Italy, and in particular the Lombardy region, was the first country in the Western hemisphere to be hit by the COVID-19 pandemic. Plasma from individuals recovered from COVID-19 (COVID-19 convalescent plasma, CCP) was the first therapeutic tool adopted to counteract the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In this retrospective cohort study, we report the experience of the city hospital of Mantua, Lombardy region, on the compassionate use of CCP in patients hospitalized for severe COVID-19. Between April 2020 and April 2021, 405 consecutive COVID-19 patients received 657 CCP units with a median anti-SARS-CoV-2 neutralizing antibody (nAb) titer of 160 (interquartile range (IQR), 80−320). Their median age was 68 years (IQR, 56−78 years), and 62% were 2022-01-01T00:00:00Z2022 Mar2026-04-08T17:34:44.691Z2025-04-06T12:09:41.447ZS-EPMC89503733533017010.3390/life12030420